These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases]. Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900 [TBL] [Abstract][Full Text] [Related]
44. [The use of capillary videomicroscopy in the therapeutic assessment of acral vasospastic phenomena: microcirculatory effect of ketanserin and nifedipine]. Gasser P Schweiz Rundsch Med Prax; 1994 Apr; 83(17):511-4. PubMed ID: 8191194 [TBL] [Abstract][Full Text] [Related]
45. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis]. Cordioli E; Virgilio S; Ghirardi R; Martinelli M Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297 [TBL] [Abstract][Full Text] [Related]
46. [The therapy of Raynaud's phenomenon]. Di Giacinto G Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530 [TBL] [Abstract][Full Text] [Related]
47. Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. Kahan A; Weber S; Amor B; Menkes CJ Lancet; 1983 Mar; 1(8323):538. PubMed ID: 6131248 [No Abstract] [Full Text] [Related]
49. Ketanserin in the treatment of progressive systemic sclerosis. Altomare GF; Pigatto PD; Polenghi MM Angiology; 1988 Jul; 39(7 Pt 1):583-6. PubMed ID: 3408023 [TBL] [Abstract][Full Text] [Related]
50. [Medical and surgical treatment of Raynaud's phenomenon]. Van de Wal HJ Phlebologie; 1987; 40(1):51-4. PubMed ID: 3554279 [No Abstract] [Full Text] [Related]
51. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study. Lau CS; McLaren M; Saniabadi A; Scott N; Belch JJ Clin Exp Rheumatol; 1991; 9(3):271-3. PubMed ID: 1879086 [TBL] [Abstract][Full Text] [Related]
52. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Fries R; Shariat K; von Wilmowsky H; Böhm M Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885 [TBL] [Abstract][Full Text] [Related]
53. [Digital necrosis in Raynaud's phenomenon revealing a testicular seminoma. Value of prostacyclin]. Taillan B; Ferrari E; Castanet J; Campagni JP; Garnier G; Fuzibet JG; Benchimol D; Dujardin P Presse Med; 1992 Jun; 21(23):1070-1. PubMed ID: 1387938 [TBL] [Abstract][Full Text] [Related]
58. The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis. Drinda S; Neumann T; Pöhlmann G; Vogelsang H; Stein G; Wolf G; Hein G Vasa; 2005 Nov; 34(4):243-9. PubMed ID: 16363279 [TBL] [Abstract][Full Text] [Related]
59. Transcutaneous electrical nerve stimulation (TENS) in Raynaud's phenomenon. Mulder P; Dompeling EC; van Slochteren-van der Boor JC; Kuipers WD; Smit AJ Angiology; 1991 May; 42(5):414-7. PubMed ID: 2035894 [TBL] [Abstract][Full Text] [Related]
60. The treatment of Raynaud's phenomenon. Seibold JR; Allegar NE Clin Dermatol; 1994; 12(2):317-21. PubMed ID: 8076271 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]